GK-1 peptide reduces tumor growth, decreases metastatic burden, and increases survival in a murine breast cancer model

Add time:08/22/2019    Source:sciencedirect.com

GK-1 is a parasite-derived peptide adjuvant of 18 amino acid-length that enhances T-cell function and increases survival in B16-F10 melanoma tumor-bearing mice. This study was designed to evaluate in vivo the antitumor efficacy of GK-1 on 4T1 mouse mammary carcinoma.BALB/c mice with palpable primary tumors were weekly intravenously injected three times with saline solution or three different concentrations (10, 50, or 100 μg per mouse) of GK-1. GK-1 significantly increased lifespan (p < 0.0001) and reduced the primary tumor weight (p = 0.014) and volume (p < 0.0001) with respect to control mice, with no statistically significant differences among GK-1 doses. At the primary tumor, we found increased necrotic areas associated with a reduction in tumor mass, as well as an increase in the antitumor cytokine IL-12. Especially encouraging is the ability of GK-1 to reduce the number of lung metastasis (p = 0.006) disregarding the dose used. The participation of IL-6 in metastasis development and the decreased levels of CCL-2, CCL-3, TNF-α, CXCL-9, GM-CSF, and b-FGF found in lungs of GK-1-treated mice is discussed.Our study supports the effectiveness of GK-1 as an antineoplastic agent that merits further exploration in combination with other therapeutic approaches in future translational studies.

We also recommend Trading Suppliers and Manufacturers of GK 86 (cas 116917-90-9). Pls Click Website Link as below: cas 116917-90-9 suppliers

Prev:Impact of the GK-1 adjuvant on peritoneal macrophages gene expression and phagocytosis
Next:Research reportThe delayed protective effect of GK-2, а dipeptide mimetic of Nerve Growth Factor, in a model of rat traumatic brain injury)